Riskpilot← Back to searchSign inGet full accessBelina Pharma AB
ABActiveOrg 5591111892Markörvägen 16Research and experimental development on natural sciences and engineering · NACE 7210Est. 20170 employees
Revenue 2024
—
EBITDA margin
—
-54% vs 2023
Equity ratio
64.5%
Financial strength
Net profit 2024
SEK -550K
-51% vs 2023
| Revenue | — | — |
| EBITDA | SEK -530K | -54% |
| Net profit | SEK -550K | -51% |
| Total assets | SEK 415K | -54% |
| Equity | SEK 268K | -36% |
| Employees | 0 | — |
Legal name
Belina Pharma AB
Org number
5591111892
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
5 maj 2017
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget skall bedriva forskning, utveckling, marknadsföring och försäljning inom det medicinska området samt idka därmed förenlig verksamhet.
Address
Markörvägen 16
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | — | — |
| Staff expenses | — | — | — | — | — |
| EBITDA | −345 | −111 | −116 | −343 | −530 |
| Depreciation & amort. | −0 | −6 | −20 | −20 | −20 |
| EBIT | −345 | −117 | −136 | −363 | −549 |
| Net financials | — | — | — | −1 | −0 |
| Profit before tax | −345 | −117 | −136 | — | — |
| Tax | −0 | −0 | −0 | — | — |
| Net profit | −345 | −117 | −136 | −364 | −550 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 544 | 1 317 | 1 136 | 898 | 415 |
| Equity | 35 | 518 | 381 | 417 | 268 |
| Long-term debt | 0 | 0 | 0 | — | — |
| Short-term debt | 509 | 800 | 754 | 481 | 148 |
| Total debt | 509 | 800 | 754 | 481 | 148 |
EBITDA margin
-52957500.0%
This company
15.8%
Market median
-335174151% vs market
20202024
Equity ratio
64.5%
This company
38.2%
Market median
+69% vs market
20202024
Return on equity
-205.3%
This company
18.4%
Market median
-1216% vs market
20202024
Net profit margin
-54966800.0%
This company
8.1%
Market median
-678602569% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.55×
This company
0.62×
Market median
+11% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
PO Audit | Audit | 2020 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2021 | |
| Board of Directors | 2021 | |
| Former (2) | ||
| Board of Directors | 2020 – 2021 | |
| Chairman | 2020 – 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
HAKMED AB
Belina Pharma AB Board members of Belina Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Peter Olof Cederblad | Audit | 0 companies |
| Bo Lennart Bruce | Board of Directors | 0 companies |
| Lars Håkan Olsson | Chairman | 0 companies |
| Olof Håkan Hjorthorn | Deputy Board Member | 0 companies |
| Lars Anton Daniel Hjorthorn | Board of Directors | 0 companies |